Group One Trading
ACRS icon

Group One Trading’s Aclaris Therapeutics ACRS Stock Holding History

Group One Trading’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30K Hold
8,000
– – ﹤0.01% 5671
2025
Q4 		$24.1K Sell
8,000
-3,700
-32% -$9.35K ﹤0.01% 6209
2025
Q3 		$22.2K Buy
+11,700
New +$20.4K ﹤0.01% 6618
2025
Q2 		– Sell
-15,000
Closed -$22.9K – 7855
2025
Q1 		$22.9K Sell
15,000
-10,700
-42% -$22.8K ﹤0.01% 5731
2024
Q4 		$63.7K Buy
25,700
+17,700
+221% +$44K ﹤0.01% 4872
2024
Q3 		$9.2K Buy
8,000
+6,100
+321% +$7.48K ﹤0.01% 5641
2024
Q2 		$2.09K Sell
1,900
-1,700
-47% -$2K ﹤0.01% 6213
2024
Q1 		$4.46K Sell
3,600
-4,200
-54% -$5.01K ﹤0.01% 6231
2023
Q4 		$8.19K Sell
7,800
-264,900
-97% -$808K ﹤0.01% 6298
2023
Q3 		$1.87M Buy
272,700
+210,800
+341% +$1.8M 0.01% 1686
2023
Q2 		$642K Sell
61,900
-11,300
-15% -$102K ﹤0.01% 2774
2023
Q1 		$592K Buy
73,200
+63,300
+639% +$803K ﹤0.01% 2605
2022
Q4 		$156K Sell
9,900
-1,400
-12% -$22.5K ﹤0.01% 4067
2022
Q3 		$178K Buy
11,300
+5,200
+85% +$81.9K ﹤0.01% 4259
2022
Q2 		$85K Sell
6,100
-4,200
-41% -$58.9K ﹤0.01% 5129
2022
Q1 		$178K Sell
10,300
-23,700
-70% -$323K ﹤0.01% 4914
2021
Q4 		$494K Buy
34,000
+31,500
+1,260% +$477K ﹤0.01% 4150
2021
Q3 		$45K Sell
2,500
-11,800
-83% -$189K ﹤0.01% 6615
2021
Q2 		$251K Sell
14,300
-18,100
-56% -$411K ﹤0.01% 4977
2021
Q1 		$816K Buy
32,400
+10,800
+50% +$211K ﹤0.01% 3483
2020
Q4 		$140K Buy
21,600
+21,200
+5,300% +$89.4K ﹤0.01% 4321
2020
Q3 		$1K Hold
400
– – ﹤0.01% 5891
2020
Q2 		$1K Sell
400
-300
-43% -$402 ﹤0.01% 5619
2020
Q1 		$1K Sell
700
-1,700
-71% -$2.31K ﹤0.01% 5043
2019
Q4 		$5K Buy
2,400
+1,400
+140% +$2.32K ﹤0.01% 4735
2019
Q3 		$1K Buy
+1,000
New +$1.42K ﹤0.01% 4962
2019
Q1 		– Sell
-16,600
Closed -$123K – 4721
2018
Q4 		$123K Buy
+16,600
New +$171K ﹤0.01% 3046
2017
Q3 		– Sell
-5,000
Closed -$136K – 4761
2017
Q2 		$136K Buy
+5,000
New +$136K ﹤0.01% 2917

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's ACRS Position: Q1 2026 in Review

Group One Trading sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 12,433 shares — an estimated $42K sold.

Group One Trading first reported a position in ACRS in Q1 2019 and held it in 23 quarters. The position peaked at $740K in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Group One Trading reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 12,433 Aclaris Therapeutics shares in Q1 2026, an estimated $42K.
  • Group One Trading first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 23 quarters.
  • Group One Trading's Aclaris Therapeutics position peaked at $740K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.